ArticleClinical and experimental immunology2022

Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies.

Roger H Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.